Adherium Ltd. · ASX:ADR
Adherium — H1 2018 Earnings Presentation
13 slides from Adherium's earnings presentation, Feb 8, 2018
Slide 1: Investor Results 1H FY18
Investor Results 1H FY18 FEBRUARY 8, 2018
Slide 2: Forward Looking Statement
Forward Looking Statement The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or
Slide 3: Recent Achievements
Recent Achievements Achieved revenue of $2.7m in H1 2018, up 92% on H1 2017 Commercial traction - Over 100,000 devices sold globally. Successful launch of Smartinhaler™ through AstraZeneca in Australia, Italy, The Netherlands, Switzerland and Austria. Delivered 18,000 connected devices during FY17 a
Slide 4: Review Results
adherium d Review Results
Slide 5: Financial Results H1 2018
Financial Results H1 2018 6 months to 6 months to Change % Dec 31, 2017 Dec 31, 2016 Revenue $2,661,000 $1,386,000 +92% Gross profit $2,047,000 $664,000 +208% Other income (grants and $439,000 $588,000 -25% interest) Operating expenses $(7,464,000) $(6,060,000) +23% Net loss $(4,978,000) $(4,808,000
Slide 6: Execution and Guidance
adherium d Execution and Guidance
Slide 7: Corporate Overview
Corporate Overview ADR: ASX Half Year Revenue 4,000 (six-month period) Market Cap $16.5M Ordinary Shares 173.9M 3,000 Options 5.8M 2,000 12 Month Share Price Range $0.07 - $0.25 1,000 Cash & Equivalents $14.9M 0 (31 Dec 2017) 1H-FY17 2H-FY17 1H-FY18 2H-FY18 * H1 2018 revenue up 92% to $2.7m and FY18
Slide 8: Strategic Priorities and Business Model
ADR Corporate Strategy • Drive expansion of existing OEM relationships into world’s largest markets • Create direct to consumer (DtC) and direct to payer (DtP) customer channels • Focus new channels on US market opportunity (US = ~50% of global TAM) Shareholder Value Creation • Increase significant
Slide 9: Strategic Priorities and Business Model - OEM
OEM – Strategic Priorities • Increase volume in existing SmartInhaler product lines by launches into new large markets • Expand product range leveraging existing OEM partnerships (beyond Symbicort) • Opportunistically evaluating new OEM distribution agreements OEM – Business Model • Innovation partn
Slide 10: Strategic Priorities and Business Model - Direct to Consumer
Direct to Consumer – Strategic Priorities • Focus only on US market (~40m Asthma and COPD patients) • Direct, digital only marketing • Highly targeted customer acquisition strategy • Subscription offering Direct to Consumer – Business Model Strategic • Online – using Facebook, Instagram, Google to r
Slide 11: Strategic Priorities and Business Model - Direct to Payer
Direct to Payer – Strategic Priorities • Launch in US market to have access to ~40m patient market size • B2B sales with initial focus on smaller, self-contained insurance systems for more rapid adoption and in market economic validation • Larger self-insured corporations focused on lowering cost of
Slide 12: Summary
Summary 1H FY18 Platform, clinical evidence, and regulatory approvals are already in place and market leading. VP of Marketing and VP of Sales are in place, US based HQ has moved to Silicon Valley. OEM Sensor shipments have shifted from clinical to commercial, roll-outs are progressing to plan, and
Slide 13: Adherium - Thank You
adherium d Adherium THANK YOU